Equities research analysts forecast that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will post $5.16 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for BioCryst Pharmaceuticals’ earnings. The lowest sales estimate is $2.91 million and the highest is $7.84 million. BioCryst Pharmaceuticals posted sales of $7.76 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 33.5%. The firm is scheduled to report its next quarterly earnings results before the market opens on Tuesday, November 7th.
According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full year sales of $5.16 million for the current financial year, with estimates ranging from $18.36 million to $29.58 million. For the next fiscal year, analysts forecast that the company will post sales of $24.56 million per share, with estimates ranging from $14.35 million to $34.66 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). The firm had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $5.79 million. BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The firm’s revenue was down 35.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.22) earnings per share.
Several brokerages recently commented on BCRX. Royal Bank Of Canada began coverage on shares of BioCryst Pharmaceuticals in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $6.00 price target for the company. BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 1st. Piper Jaffray Companies restated an “overweight” rating and issued a $15.00 price target (up previously from $13.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 5th. ValuEngine downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, September 3rd. Finally, J P Morgan Chase & Co upped their price target on shares of BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the company a “neutral” rating in a research report on Wednesday, September 6th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $8.78.
BioCryst Pharmaceuticals (BCRX) traded up 1.58% during mid-day trading on Friday, reaching $4.50. 1,024,341 shares of the company’s stock traded hands. The company’s market capitalization is $361.93 million. The company has a 50-day moving average of $5.08 and a 200-day moving average of $5.38. BioCryst Pharmaceuticals has a 52-week low of $3.75 and a 52-week high of $9.25.
COPYRIGHT VIOLATION WARNING: “BioCryst Pharmaceuticals, Inc. (BCRX) Expected to Announce Quarterly Sales of $5.16 Million” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.com-unik.info/2017/10/31/biocryst-pharmaceuticals-inc-bcrx-expected-to-announce-quarterly-sales-of-5-16-million.html.
In other BioCryst Pharmaceuticals news, Director Fred E. Cohen sold 54,250 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $5.42, for a total value of $294,035.00. Following the transaction, the director now owns 173,660 shares in the company, valued at approximately $941,237.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 5.80% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of BioCryst Pharmaceuticals by 19.9% during the 2nd quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock worth $33,404,000 after purchasing an additional 996,052 shares during the last quarter. RA Capital Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 47.9% during the 2nd quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock worth $28,702,000 after purchasing an additional 1,672,447 shares during the last quarter. State Street Corp increased its stake in shares of BioCryst Pharmaceuticals by 72.0% during the 2nd quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock worth $21,736,000 after purchasing an additional 1,636,909 shares during the last quarter. FMR LLC increased its stake in shares of BioCryst Pharmaceuticals by 114.5% during the 2nd quarter. FMR LLC now owns 3,124,676 shares of the biotechnology company’s stock worth $17,373,000 after purchasing an additional 1,667,791 shares during the last quarter. Finally, Jennison Associates LLC increased its stake in shares of BioCryst Pharmaceuticals by 12.8% during the 2nd quarter. Jennison Associates LLC now owns 2,080,818 shares of the biotechnology company’s stock worth $11,569,000 after purchasing an additional 236,182 shares during the last quarter. Hedge funds and other institutional investors own 70.18% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about BioCryst Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioCryst Pharmaceuticals Inc. and related companies.